Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Galectin Therapeutics Inc.

Headquarters: Norcross, GA, United States of America
Year Founded: 2000
Status: Public
Industry Sector: HealthTechnology
CEO: Joel Lewis, CPA
Number Of Employees: 14
Enterprise Value: $148,233,940
PE Ratio: -2.31
Exchange/Ticker 1: NASDAQ:GALT
Exchange/Ticker 2: N/A
Latest Market Cap: $104,677,600

BioCentury | Dec 16, 2024
Distillery Therapeutics

Inhibiting LGALS1 for myelofibrosis

BioCentury | Aug 3, 2024
Management Tracks

Dannielle Appelhans to lead Cour

Plus: Context hires Ullmann, Andreas, and updates from Galectin, Exagen, Candid, Amgen and Hummingbird
BioCentury | Sep 1, 2021
Management Tracks

Zaks joins board at Teva

Jogerst named CBO at Rubius, plus updates from Telix, Talis, Ziopharm, Pyxis and more
BioCentury | Sep 3, 2020
Management Tracks

Dier joining Ultragenyx as CFO; plus Magenta, Galectin, Immunicum, BrainStorm, Vaccinex

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) hired Mardi Dier as EVP and CFO. She will succeed Shalini Sharp, who will remain CFO until the former CFO and CBO of Portola Pharmaceuticals Inc.
BioCentury | Aug 21, 2019
Distillery Therapeutics

LGALS3 identified as Huntington disease target

BioCentury | Jun 13, 2018
Company News

Management tracks: Salk Institute, Galectin

Items per page:
1 - 10 of 61